Bolt Biotherapeutics, Inc. SEC filings BOLT

Bolt Biotherapeutics, Inc. has 294 filings in SEC EDGAR's recent list, going back to May 7, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (material agreement, agreement ended, acquisition or sale of assets, unregistered share sale, officer or director change, bylaw or fiscal year change, regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Bolt Biotherapeutics, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
10-Q Quarterly report May 12, 2026 Mar 31, 2026
10-Q Quarterly report Nov 12, 2025 Sep 30, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025
10-Q Quarterly report May 12, 2025 Mar 31, 2025
10-Q Quarterly report Nov 12, 2024 Sep 30, 2024
10-Q Quarterly report Aug 13, 2024 Jun 30, 2024
10-Q Quarterly report May 14, 2024 Mar 31, 2024
10-Q Quarterly report Nov 9, 2023 Sep 30, 2023
10-Q Quarterly report Aug 7, 2023 Jun 30, 2023
10-Q Quarterly report May 11, 2023 Mar 31, 2023
10-Q Quarterly report Nov 10, 2022 Sep 30, 2022
10-Q Quarterly report Aug 10, 2022 Jun 30, 2022
10-Q Quarterly report May 12, 2022 Mar 31, 2022
10-Q Quarterly report Nov 9, 2021 Sep 30, 2021
10-Q Quarterly report Aug 12, 2021 Jun 30, 2021
10-Q Quarterly report May 13, 2021 Mar 31, 2021

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BOLT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Redwood City, CA
SEC filer status
, Emerging growth company
SEC CIK
1641281
Former names
Bolt Therapeutics, Inc. (until May 7, 2015)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.